3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
46
Sarcoma
21
Neoplasms
18
Neoplasm Metastasis
15
Ovarian Neoplasms
12
Breast Neoplasms
10
Carcinoma, Non-Small-Cell Lung
8
Recurrence
5
Melanoma
5
Fallopian Tube Neoplasms
5
Thyroid Neoplasms
4
Prostatic Neoplasms
4
Liposarcoma
4
Hemangiosarcoma
4
Urinary Bladder Neoplasms
3
Solid Tumors
3
Lung Neoplasms
3
Leiomyosarcoma
3
Kidney Neoplasms
3
Glioblastoma
3
Colorectal Neoplasms
3
Clear-cell metastatic renal cell carcinoma
3
Carcinoma, Ovarian Epithelial
3
Thyroid Carcinoma, Anaplastic
2
Sarcoma, Synovial
2
Refractory Solid Tumors
2
Neuroendocrine Tumors
2
Gliosarcoma
2
Financial Stress
2
Chondrosarcoma, Extraskeletal Myxoid
2
Interventions
pertuzumab
1
pazopanib
1
daratumumab
1
Trastuzumab
1
Surgical Procedures, Operative
1
Sunitinib
1
Sorafenib
1
Risk Assessment
1
Radiotherapy
1
Injections, Subcutaneous
1
Focus Groups
1
Bandages, Hydrocolloid
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Patient Preference
×
pazopanib
×
Clear all
NCT01064310
2017-04-17
PISCES
Novartis
Phase 3
Completed
169 enrolled
16 charts